Background. Antiviral prophylaxis has been shown to decrease the incidence of
cytomegalovirus (CMV) disease in organ transplant recipients, but whether CMV disease …

We assessed the impact of antiviral prophylaxis and preemptive therapy on the incidence
and outcomes of cytomegalovirus (CMV) disease in a nationwide prospective cohort of solid …

Background. The incidence and impact of cytomegalovirus (CMV) disease that occurs
despite CMV prophylaxis among liver transplant recipients have been incompletely defined …

BACKGROUND: Late-onset CMV disease is being increasingly recognized as a significant
post-transplantation complication. OBJECTIVES: To discern the impact of antiviral …

Background: Cytomegalovirus (CMV) infection of solid organ transplant (SOT) recipients
causes both ''direct''and ''indirect''effects including allograft rejection, decreased graft and …

In the era of effective antiviral chemoprophylaxis, cytomegalovirus (CMV) disease has been
inconsistently associated with increased mortality in liver transplant (LT) recipients. A …

Cytomegalovirus (CMV) infection is an opportunistic infection frequently found after solid
organ transplantation, and it contributes significantly to mortality and morbidity. CMV …

Clinical practice guidelines recommend antiviral prophylaxis to cytomegalovirus (CMV)
donor‐positive/recipient‐negative (D+/R−) liver transplant recipients. We assessed the …

The benefits of cytomegalovirus (CMV) prophylaxis in preventing the direct effects of CMV
infection and disease are well established; however, the impact of exposure to antiviral …

Background. Cytomegalovirus (CMV) disease after discontinuation of prophylaxis is a
significant problem for CMV-seronegative recipients of CMV-seropositive organs (donor …